Physician

Thomas James Andrews, M.D.

According to 2025 Medicare claims, Thomas Andrews, M.D. (NPI: 1245393651) practices psychiatry in the Redding, CA market, with the plurality of this provider's patient population coming from Shasta, CA. This provider's primary affiliated billing organization is THOMAS J ANDREWS MD INC (NPI: 1588793657; TIN: 680342989) and primary practice location at 96002-1148.

Andrews' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 744 traditional Medicare patients, billed 7,055 HCPCS/CPT codes, and received $835,093 in Medicare payments. The top billing code was G0483 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 2,483 prescription claims across 180 beneficiaries totaling $271,325 in drug costs, led by Nuedexta (Dextromethorphan Hbr/Quinidine). Open Payments data shows 44 records totaling $4,966. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $1,801,860 to $271,325. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	577	15,939	$526,711
2016	602	4,490	$361,048
2017	552	4,466	$351,273
2018	620	5,322	$422,666
2019	648	7,091	$490,894
2020	691	6,692	$551,499
2021	690	4,632	$446,953
2022	715	5,651	$481,387
2023	767	6,157	$505,554
2024	744	7,055	$835,093

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	422	10,929	$1,801,860
2016	394	9,962	$1,557,809
2017	365	8,667	$1,165,208
2018	351	8,144	$1,089,272
2019	382	8,501	$1,678,046
2020	326	7,509	$1,827,305
2021	280	4,923	$729,934
2022	181	2,815	$440,223
2023	197	2,725	$463,204
2024	180	2,483	$271,325

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	253	319	$241
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	577	2,045	$88
80307	Testing for presence of drug, by chemistry analyzers	421	593	$61
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	522	1,563	$58
99442	Telephone medical discussion with physician, 11-20 minutes	143	185	$46

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nuedexta	Dextromethorphan Hbr/Quinidine	12	360	$18,604
Mounjaro	Tirzepatide	12	336	$12,664
Belsomra	Suvorexant	20	600	$8,504
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	108	4,508	$7,277
Vyvanse	Lisdexamfetamine Dimesylate	15	450	$5,770

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	44	$4,966	Teva Pharmaceuticals USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas James Andrews, M.D.?

Tedicare shows public-source Medicare data for Thomas James Andrews, M.D. (NPI 1245393651), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas James Andrews, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Thomas James Andrews, M.D.?

Thomas James Andrews, M.D. is linked to THOMAS J ANDREWS MD INC (billing NPI 1588793657) in the available physician profile data.

Does Thomas James Andrews, M.D. have Open Payments data?

Thomas James Andrews, M.D. has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.